If you are considering starting a weight loss medication, or you have already begun treatment and want to know what to expect, one of the most common questions is: How much weight can you lose in a month? The answer is not a single number. It depends on the medication, your starting weight, your lifestyle, and how your body responds to treatment.
At The Care Pharmacy, our prescribing team works with patients across the UK to help them achieve safe and sustainable results. Before we explore the detail, get in touch if you have questions, or complete our online consultation to find out whether you are eligible for weight-loss medication.
Contents
Quick Answer
On a GLP-1 or dual GIP/GLP-1 weight loss medication such as Wegovy or Mounjaro, most patients lose between 1–2 kg (approximately 2–4 lbs) per month on average, though results vary. It is important to note that each weight loss journey is different. In the first month, weight loss may be more modest as the body adjusts to a starter dose. Over the full treatment course, clinical trials show average total weight loss of around 15–22% of body weight (approximately 15% for semaglutide and up to 20–22% for tirzepatide) at the highest approved doses. It’s worth noting that these figures come from controlled clinical trial settings alongside lifestyle counselling, and real-world results may be somewhat lower. Lifestyle factors including diet, activity, and consistency significantly influence your individual results.
The most clinically effective weight loss medications currently available in the UK work by mimicking a natural gut hormone called glucagon-like peptide-1 (GLP-1). This hormone is released after eating and plays a central role in appetite regulation and blood sugar control.
GLP-1 receptor agonists such as Mounjaro and Wegovy produce several effects that support weight loss:
Mounjaro (tirzepatide) also activates the GIP receptor, making it a dual agonist. This additional mechanism is thought to contribute to its higher average weight loss compared with GLP-1-only medicines.
These medications are not a substitute for a healthy lifestyle. They are tools that help you eat less and make better choices by reducing biological hunger signals — but consistent diet and movement remain essential to maximising results.
Weight loss is rarely linear. Some months you may lose more; others, progress may be slower or even pause temporarily. As a general guide:
It is worth noting that clinical trial results reflect averages. Some patients lose considerably more; others less. Your starting weight, how closely you follow dietary guidance, your activity level, and how you respond to the medication all play a role.
In the SURMOUNT-1 trial for Mounjaro, participants lost an average of approximately 20–21% of their total body weight over 72 weeks at the highest 15 mg dose. For someone starting at 100 kg, that equates to around 20 kg lost over roughly 18 months — or an average of just over 1 kg per month across the full treatment period, with faster losses earlier and a gradual slowdown as weight decreases.
Both Mounjaro and Wegovy are MHRA-approved weight loss injections available in the UK. Here is how they compare across key criteria:
| Feature | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Drug class | Dual GIP/GLP-1 agonist | GLP-1 agonist |
| Administration | Once-weekly injection | Once-weekly injection |
| Starting dose | 2.5 mg weekly | 0.25 mg weekly |
| Maximum dose | 15 mg weekly | 2.4 mg weekly (2.4 mg standard; 7.2 mg new higher dose — see note below) |
| Average weight loss (clinical trials) | Up to ~20–21% at 15 mg (72 weeks) | ~14–17% at 2.4 mg (68 weeks) |
| Common side effects | Nausea, diarrhoea, constipation, reduced appetite, vomiting | Nausea, diarrhoea, constipation, headache, fatigue |
| Manufacturer | Eli Lilly | Novo Nordisk |
| UK availability (private) | Available from £149.99 at The Care Pharmacy | Available privately following consultation |
| Suitable for type 2 diabetes | Yes — also MHRA-approved for T2D | Yes — also approved as Ozempic for T2D |
Two patients on the same medication and dose can lose very different amounts of weight in a month. This is normal, and several factors help explain the variation:
Getting the most from your treatment is about combining the medication with smart lifestyle habits. Here are some evidence-informed strategies to help you make the most of each month:
The first month is often characterised by adjustment rather than dramatic transformation. Here is what many patients experience:
Do not be disheartened if the first month does not produce dramatic results. The starter dose is designed for tolerability, not maximum efficacy. Progress builds as the dose escalates over the following weeks and months.
Plateaus are a normal part of the weight loss process — even on medication. If your monthly weight loss has stalled, consider the following before assuming you need a higher dose:
If you have reviewed all of the above and weight loss remains stalled for several weeks despite good adherence, a clinical review may be appropriate to discuss whether a dose escalation is right for you.
Click on each question to reveal the answers you are looking for:
Most patients on Mounjaro lose between 1 and 3 kg per month, though this varies significantly depending on the dose, diet, activity level, and individual response. In the first month on the 2.5 mg starter dose, losses tend to be modest. As the dose increases over subsequent months, many patients see more consistent results. Across the full SURMOUNT-1 clinical trial, average weight loss at the highest 15 mg dose was approximately 20–21% of body weight over 72 weeks.
Wegovy (semaglutide) typically produces average weight loss of around 14–17% of total body weight over 68 weeks at the 2.4 mg maintenance dose. On a monthly basis, this translates to roughly 1–2.5 kg per month on average, with faster losses earlier in treatment and a gradual plateau as body weight decreases. As with all GLP-1 medications, individual results vary based on lifestyle and biology.
Losing 1 stone (approximately 6.35 kg) in a single month is unlikely for most patients on a GLP-1 medication, particularly during the early titration phase. A loss of this magnitude in one month would be considered very fast and is not typically what clinical evidence supports as an average. Sustainable weight loss of 0.5–1 kg per week is generally considered the safe and healthy range, and most medication-supported patients fall within or slightly above this. Very rapid weight loss can increase the risk of muscle loss and nutritional deficiency.
Not always. Higher doses generally improve appetite suppression, which can support greater calorie reduction — but weight loss does not always accelerate linearly with each dose increase. Some patients find that moving from 5 mg to 7.5 mg Mounjaro produces a noticeable improvement in results; others find their best results at a middle dose rather than the maximum. Dose escalation should always be guided by clinical assessment, not solely by the desire for faster results.
Most clinical guidelines recommend a rate of 0.5–1 kg per week as a safe and sustainable target, which equates to approximately 2–4 kg per month. Losing at this rate helps preserve muscle mass and minimises the risk of nutritional deficiencies. Very rapid weight loss — particularly above 1.5 kg per week — may increase the risk of gallstones, muscle loss, and fatigue. Weight loss medications tend to produce results within or slightly above this healthy range when combined with appropriate lifestyle habits.
Severely restricting calories while on a GLP-1 medication is not recommended and may be counterproductive. Eating too little — particularly protein — increases the risk of muscle loss, nutritional deficiency, fatigue, and hair thinning. It can also slow your metabolic rate, making weight loss harder in the long run. Focus on eating sufficient protein (at least 1.2 g per kg of body weight per day), plenty of vegetables, and reducing calorie-dense processed foods. Let the medication do its job by reducing appetite naturally rather than trying to out-restrict it.
Clinical evidence suggests that a significant proportion of patients do regain some weight after stopping GLP-1 medications, particularly if lifestyle habits have not been firmly established. This is because the biological mechanisms that drive hunger return when the medication is discontinued. The best approach is to use the treatment period to embed long-term dietary and activity habits so that when you eventually stop or reduce medication, the behaviours that support a healthy weight are already in place. Your prescribing team can advise on a personalised exit strategy when the time comes.
The clearest sign is a reduction in appetite and food intake. Even before the scales move significantly, most patients notice reduced cravings, smaller portion sizes, and less interest in snacking. Over weeks and months, these changes should produce measurable weight loss. If you have been on a stable, therapeutic dose for four or more weeks with no change in appetite, food intake, or weight, a clinical review is worthwhile to assess whether your current dose remains appropriate.
Understanding how much weight you can lose in a month on weight loss medication means managing expectations sensibly. Most patients lose between 1 and 3 kg per month depending on the medication, dose, and lifestyle factors. Results accumulate over months, not days — and the patients who see the best outcomes are those who commit to both their medication and their habits simultaneously.
At The Care Pharmacy, we provide personalised clinical oversight throughout your weight loss journey. Whether you are considering starting treatment or want to review your current results, our prescribing team is here to support you every step of the way. Reach out to our team, or complete our online consultation to find out whether weight-loss medication is right for you.
The most effective MHRA-approved weight loss injection currently available in the UK. Mounjaro is a dual GIP/GLP-1 receptor agonist, offering average weight loss of approximately 20–21% at the highest 15 mg dose. Administered as a once-weekly injection using a simple pre-filled pen.
Mounjaro starts from £149.99 at The Care Pharmacy.
The established GLP-1 weight loss injection from Novo Nordisk, with a substantial body of published clinical and real-world evidence. Wegovy typically helps patients achieve average weight loss of 14–17%, administered as a once-weekly injection.
Wegovy is available privately from £99.99 through The Care Pharmacy following a clinical consultation.
The original GLP-1 weight loss injection, offering a proven and well-established treatment option for those looking to manage their weight. Nevolat (liraglutide) typically helps patients achieve average weight loss of 5–8%, administered as a once-daily injection using a pre-filled pen.
Nevolat starts from £124.99 at The Care Pharmacy.
A widely used GLP-1 receptor agonist from Novo Nordisk, with an extensive clinical track record in weight management. Saxenda typically helps patients achieve average weight loss of 5–8%, administered as a once-daily injection with a flexible dosing pen.
Saxenda is available privately from £279.99 through The Care Pharmacy following a clinical consultation.
This article was written by Pharmacy Mentor and clinically reviewed by Mohammed Ismail Lakhi, MPharm, MRPharm, Superintendent Pharmacist at The Care Pharmacy. Mohammed is registered with the General Pharmaceutical Council (GPhC registration number 2072815) and leads clinical governance across The Care Pharmacy’s weight management services.
Last reviewed: May 2026
Disclaimer: This article is for general information only and is not a substitute for individual medical advice. Always consult a qualified prescriber before starting any prescription weight loss treatment.
Medically reviewed by
Superintendent Pharmacist
If you have been searching for Wegovy in the UK, you are not alone. Demand for semaglutide has grown significantly since its MHRA approval, and patients are increasingly asking where they can access it, how quickly, and at what cost. The short answer is that access has improved considerably in 2026 — but the route […]
Mounjaro Price Comparison UK Guide · Updated March 2026 The same pen. The same manufacturer. Up to £100/month difference in price depending on where you buy it. This is the most comprehensive Mounjaro price comparison UK guide available — every dose, every hidden cost, NHS vs private access, and how to buy safely from a […]
If you are worried about unprotected sex or contraceptive failure, acting quickly can make all the difference. ellaone tablets are a widely used form of emergency contraception, but they are not always the right choice for everyone. At The Care Pharmacy, we provide discreet access to emergency contraception through our secure consultation form, alongside clear […]
If you are starting to think seriously about weight management, BMI is often one of the first things people look at. A quick check can help you understand whether your weight may be affecting your health, and what support options might be available to you. One of the easiest ways to begin is by using […]
Are you currently taking Ozempic for weight loss? And wondering if you could switch to Wegovy, licensed for chronic weight management. GLP-1 receptors like Ozempic and Wegovy have been in the limelight since 2017. Switching from Ozempic to Wegovy is a decision that should be made with the guidance of your healthcare provider and […]
Mindful Eating: How to Develop Healthy Relationship with Food Have you ever found yourself at the bottom of a tub of ice cream without recalling the delicious journey that got you there? Or wolfed down a meal while working or watching your favourite series, barely registering what you ate? If the answer is yes, […]
